296
Participants
Start Date
August 21, 2013
Primary Completion Date
November 30, 2015
Study Completion Date
March 2, 2020
COBRA PzF
Paul Stradins Clinical University Hospital, Riga
Lenox Hill Hospital, New York
Clinical Center of Serbia, Belgrade
Mount Sinai Hospital, New York
St Joseph's Hospital, Liverpool
Clinique Axium, Aix-en-Provence
York General Hospital, York
Virginia Cardiovascular Specialists, Richmond
Hospital Clinico San Carlos, Madrid
Emory University Hospital, Atlanta
Mt Sinai Medical Center, Miami Beach
Heart Center of Indiana, Indianapolis
Aspirus Heart & Vascular Institute, Wausau
Sankt Kathatinen Hospital, Frankfurt
Centre Hospitalier de Pau, Pau
Albert Schweitzer Hospital, Colmar
Clinique du Diaconat, Mulhouse
Louisiana Heart Hospital, Lacombe
Oklahoma Foundation for Cardiovascular Research, Oklahoma City
The Heart Hospital Baylor Plano, Plano
Cardiology Consultants of Texas, Dallas
Tyler Cardiovascular Consultants, Tyler
Plaza Medical Center, Fort Worth
Clinique St. Hilaire, Rouen
Houston Methodist Hospital, Houston
San Antonio Endovascular & Heart Institute, San Antonio
Texas Cardiac Center, Lubbock
Kardiologische Praxis und Praxisklinik, München
Hopital Henri Duffaut, Avignon
Bakersfield Memorial Hospital, Bakersfield
Southern Oregon Cardiology, Medford
Beth Israel Deaconess Medical Center, Boston
Deborah Heart & Lung Center, Browns Mills
Hospital de la Santa Creu, Barcelona
Kantonsspital St. Gallen, Sankt Gallen
Lead Sponsor
CeloNova BioSciences, Inc.
INDUSTRY